Cumberland Pharmaceuticals IncNASDAQ:CPIX
- LAST PRICE1.4000
- TODAY'S CHANGE (%)0.0300 (2.1898%)
- Bid / Lots1.3000/ 15
- Ask / Lots1.3400/ 3
- Open / Previous Close1.3500 / 1.3700
- Day Range
- 52 Week Range
- Volume290,815
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CPIX |
|---|---|---|
| 09:32 ET | 6693 | 1.35 |
| 09:33 ET | 1302 | 1.3192 |
| 09:35 ET | 130 | 1.3497 |
| 09:39 ET | 1334 | 1.33 |
| 09:42 ET | 1382 | 1.35 |
| 09:44 ET | 2123 | 1.36 |
| 09:46 ET | 9805 | 1.34 |
| 09:48 ET | 1700 | 1.345 |
| 09:50 ET | 874 | 1.34 |
| 09:51 ET | 1319 | 1.3401 |
| 09:55 ET | 22434 | 1.325 |
| 09:57 ET | 26886 | 1.31 |
| 10:00 ET | 16262 | 1.2501 |
| 10:02 ET | 10967 | 1.25 |
| 10:04 ET | 1059 | 1.27 |
| 10:06 ET | 2321 | 1.29 |
| 10:08 ET | 800 | 1.2607 |
| 10:09 ET | 1341 | 1.28 |
| 10:11 ET | 5040 | 1.28 |
| 10:13 ET | 3250 | 1.26 |
| 10:15 ET | 11208 | 1.2899 |
| 10:20 ET | 400 | 1.275 |
| 10:22 ET | 1600 | 1.2701 |
| 10:26 ET | 2000 | 1.27 |
| 10:27 ET | 546 | 1.2707 |
| 10:36 ET | 3737 | 1.31 |
| 10:38 ET | 300 | 1.31 |
| 10:42 ET | 1385 | 1.34 |
| 10:44 ET | 208 | 1.3301 |
| 10:49 ET | 400 | 1.32 |
| 10:54 ET | 100 | 1.31 |
| 11:00 ET | 680 | 1.3362 |
| 11:05 ET | 1000 | 1.33 |
| 11:09 ET | 4074 | 1.3339 |
| 11:12 ET | 1700 | 1.34 |
| 11:18 ET | 900 | 1.34 |
| 11:20 ET | 879 | 1.32 |
| 11:21 ET | 100 | 1.335 |
| 11:32 ET | 3100 | 1.34 |
| 11:36 ET | 459 | 1.3398 |
| 11:39 ET | 1000 | 1.34 |
| 11:45 ET | 1200 | 1.3513 |
| 12:01 ET | 100 | 1.35 |
| 12:03 ET | 190 | 1.33 |
| 12:24 ET | 1400 | 1.35 |
| 12:26 ET | 4524 | 1.37 |
| 12:32 ET | 4400 | 1.3859 |
| 12:33 ET | 11716 | 1.4105 |
| 12:35 ET | 11939 | 1.43 |
| 12:39 ET | 3145 | 1.43 |
| 12:42 ET | 1250 | 1.41 |
| 12:44 ET | 1300 | 1.4 |
| 12:48 ET | 10069 | 1.38 |
| 12:50 ET | 5020 | 1.38 |
| 12:51 ET | 11110 | 1.3509 |
| 12:53 ET | 1300 | 1.4 |
| 12:57 ET | 4817 | 1.37 |
| 01:00 ET | 913 | 1.4 |
Nov 7, 2024
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
4:05PM ET on Thursday Nov 07, 2024 by Dow Jones*DJ Cumberland Pharma 3Q Loss/Shr 11c >CPIX, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
Nov 5, 2024
New Study Compares Caldolor(R) (ibuprofen injection) to ketorolac, from 4:05PM ET on Tuesday Nov 05, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 05, 2024 by Dow Jones
Oct 31, 2024
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS, from 4:05PM ET on Thursday Oct 31, 2024 by Dow Jones
4:05PM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cumberland Pharmaceuticals Inc | 15.6M | -1.8x | --- |
Aoxing Pharmaceutical Company Inc | 2.8M | -0.7x | --- |
Universe Pharmaceuticals Inc | 2.7M | 0.0x | --- |
Tibet Pharmaceuticals Inc | 10.0 | 0.0x | --- |
YourWay Cannabis Brands Inc | 200.0 | 0.0x | --- |
Aida Pharmaceuticals Inc | 8.1K | 0.0x | --- |
Company Information
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever, Kristalose for oral solution, a prescription laxative, for the treatment of constipation, and Omeclamox-Pak, oral, for the treatment of Helicobacter pylori infection and related duodenal ulcer disease. Its brands also include Sancuso transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia, and Vibativ injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia.
Contact Information
- Headquarters
- 2525 W End Ave Ste 950NASHVILLE, TN, United States 37203-1608
- Phone
- 615-255-0068
- Fax
- 615-255-0094
Executives
- Chairman of the Board, Chief Executive Officer
- A. Kazimi
- Chief Financial Officer, Vice President
- John Hamm
- Senior Vice President, Chief Compliance Officer
- James Herman
- Vice President of Sales and Marketing
- Chris Bitterman
- Vice President - Organizational Development
- Todd Anthony
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.6M |
|---|---|
Revenue (TTM) | $36.8M |
Shares Outstanding | 14.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.29 |
EPS | $-0.77 |
Book Value | $2.10 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | 0.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -29.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
